Core Viewpoint - Yiming Oncology-B (01541) saw a stock increase of over 7%, currently trading at 14.4 HKD with a transaction volume of 29.21 million HKD, following the announcement of clinical trial applications for its drug IMM2510 aimed at treating immune therapy-resistant non-small cell lung cancer (NSCLC) [1] Group 1: Clinical Trial Developments - The company has submitted an application to the National Medical Products Administration for a Phase III clinical trial of IMM2510 for treating immune therapy-resistant NSCLC [1] - Additionally, two Phase III registration clinical trials for different types of lung cancer have been submitted recently [1] Group 2: Research Data - Recent Phase I study data presented at the 2025 World Lung Cancer Conference showed that among 17 evaluable patients with advanced squamous NSCLC who had previously received immune therapy, IMM2510 achieved an objective response rate (ORR) of 35.3% and a disease control rate (DCR) of 76.5% (13/17) [1] - The median duration of response (DoR) was reported as 7.59 months (95% CI: 4.07 - NA), and the median progression-free survival (PFS) was 9.4 months (95% CI: 1.87 - NA) [1]
港股异动 | 宜明昂科-B(01541)涨超7% 提交IMM2510的III期临床试验申请